newsfilter
← Latest News
GlobeNewswire·

Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT) (the "Company") today announced its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen